A class action lawsuit has been filed against DexCom Inc. on behalf of investors who suffered losses between January 8, 2024, and September 17, 2025, due to alleged securities fraud. The complaint alleges that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without FDA approval. These changes reportedly made the devices less reliable and posed significant health risks to users. It is further alleged that DexCom overstated the reliability, accuracy, and functionality of the G7, downplayed the severity of the issues, and misrepresented the company's exposure to regulatory and financial risks. The ongoing litigation seeks to recover damages for shareholders affected by these alleged misstatements.